NOVO NORDISK A/S |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 882.4 DKK | -1.71% |
|
-1.73% | +25.47% |
| 12:26pm | NOVO NORDISK : JP Morgan gives a Buy rating | ZD |
| 12:08pm | North American Morning Briefing : Stock Futures Rise as More Earnings Roll In | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
06:30am
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
897.7
DKK
Average target price
904.2
DKK
Spread / Average Target
+0.72%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +25.47% | 571B | |
| +33.25% | 699B | |
| -3.55% | 364B | |
| +18.16% | 326B | |
| +4.36% | 286B | |
| +14.87% | 236B | |
| +4.94% | 198B | |
| -10.14% | 194B | |
| -3.69% | 149B | |
| -5.59% | 154B |
- Stock Market
- Equities
- NOVO B Stock
- News Novo Nordisk A/S
- Sector Update: Health Care
